NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES

摘要

The present invention concerns improved methods and compositions for neoadjuvant use of antibody-drug conjugates (ADCs) in cancer therapy, preferably ADCs comprising an anthracycline or camptothecin, more preferably SN-38 or pro-2-pyrrolinodoxorubicin (P2PDox). The ADC is administered as a neoadjuvant, prior to treatment with a standard anti-cancer therapy such as surgery, radiation therapy, chemotherapy, or immunotherapy. Neoadjuvant use of the ADC substantially improves the efficacy of standard anti-cancer therapy and may debulk a primary tumor or eliminate micrometasteses. In most preferred embodiments, neoadjuvant ADC in combination with a standard anti-cancer therapy is successful in treating cancers that are resistant to standard treatments, such as triple-negative breast cancer (TNBC).

主权项

1. A method for neoadjuvant treatment of cancer comprising:
a) administering an antibody-drug conjugate (ADC) to a subject with cancer, wherein the drug is selected from the group consisting of an anthracycline and a camptothecin; and b) treating the subject with a standard anti-cancer therapy selected from the group consisting of surgery, radiation therapy, chemotherapy, and immunotherapy, wherein the ADC is administered before the standard anti-cancer therapy.